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Abstract
Background: Rapid diagnostic tests (RDTs) are becoming increasingly indispensable in malaria
management, as a means of increasing the accuracy of diagnosis. The WHO has issued
recommendations, but the selection of the most suitable RDT remains difficult for users in endemic
countries. The genetic variability of the antigens detected with RDTs has been little studied, but
may affect the sensitivity of RDTs. This factor has been studied by comparisons between countries
at continental level, but little information is available concerning antigen variability within a given
country.
Methods:  A country-wide assessment of polymorphism of the PfHRP2, PfHRP3, pLDH and
aldolase antigens was carried out in 260 Plasmodium falciparum and 127 Plasmodium vivax isolates,
by sequencing the genes encoding these antigens in parasites originating from the various
epidemiological strata for malaria in Madagascar.
Results: Higher levels of polymorphism were observed for the pfhrp2 and pfhrp3 genes than for
the P. falciparum and P. vivax aldolase and pldh genes. Pfhrp2 sequence analysis predicted that 9% of
Malagasy isolates would not be detected at parasite densities ≤ 250 parasites/μl (ranging from 6%
in the north to 14% in the south), although RDTs based on PfHRP2 detection are now
recommended in Madagascar.
Conclusion: These findings highlight the importance of training of health workers and the end
users of RDTs in the provision of information about the possibility of false-negative results for
patients with clinical symptoms of malaria, particularly in the south of Madagascar.
Background
Since the emergence and spread of Plasmodium falciparum
parasites resistant to inexpensive anti-malarial drugs, such
as chloroquine (CQ) and sulphadoxine-pyrimethamine
(SP), routine malaria case management has changed in
endemic countries, such as Madagascar. Malaria diagnosis
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in these areas – particularly in zones not well covered by
healthcare facilities – was entirely based on clinical exam-
ination, with CQ widely administered for any fever with
no obvious alternative cause [1-3]. Since the introduction
of more effective, more expensive anti-malarial drug com-
binations, such as artemisinin combination therapy
(ACT), the WHO recommends the establishment of an
accurate biological diagnosis before treatment and the
withdrawal of presumptive anti-malarial treatment for all
patients other than children under the age of five years in
hyperendemic areas. This change in medical practice is
now a public health priority in Africa, ensuring that effec-
tive anti-malarial drugs are administered only to the
patients who need them and limiting the unnecessary use
of inappropriate treatment, exposure to potential drug
toxicity and the development of drug resistance.
The detection of Plasmodium species by the examination
of blood films under a microscope remains the gold
standard method for malaria diagnosis. However, this
method, despite its simplicity and low cost, is not availa-
ble everywhere. In peripheral health centres, in particular,
there may be no appropriate microscope in working order
or a lack of consumables, such as slides or Giemsa stain,
or the staff may not have received appropriate training [4].
The development of alternative diagnostic tests for
malaria, such as rapid diagnostic tests (RDTs), over the
last ten years has made it possible to extend biological
diagnosis to remote areas with few resources. These lat-
eral-flow immunochromatographic tests detect specific
antigens produced by malaria parasites and are rapid and
simple to carry out, requiring no electricity or specific
equipment [5-7]. A large number of branded RDT prod-
ucts are now available commercially (86 RDT products
from 28 manufacturers), but all are based on the same
principle and only three groups of antigen are detected.
Most products detect P. falciparum-specific proteins, either
P. falciparum histidine-rich protein 2 (PfHRP2) or P. falci-
parum  lactate dehydrogenase (Pf-pLDH). Some detect
both falciparum-specific and pan-specific antigens (aldo-
lase or pan-malaria pLDH), distinguishing non-falciparum
infections from P. falciparum or mixed infections.
Increase in the funding of malaria control has resulted in
the National Malaria Control Programmes (NMCPs) of
many endemic countries considering the possible use of
RDTs in health facilities. The choice of an appropriate
RDT is based on a number of factors, including sensitivity
and specificity, stability, ease of use, cost, the prevalence
of the various species infecting humans (choice between
RDT detecting only P. falciparum or both P. falciparum and
non-falciparum  infections) and the format of the RDT.
However, many factors, relating to either the parasite or
the user, may affect the performance of RDTs for malaria
[8,9]. Diversity in the genes encoding the proteins
detected by the RDT may be a particularly important par-
asite factor. This has been demonstrated for PfHRP2, for
which extensive diversity has been shown to affect the
detection limits of RDTs based on PfHRP2 detection
[10,11]. However, the degree of antigen variation has
recently been shown to be limited for pLDH and parasite
aldolase [12,13], suggesting that antigen polymorphism is
unlikely to be responsible for sensitivity variation.
This study, designed to guide the NMCP in Madagascar in
its choice of RDT for malaria, had the following objec-
tives: (i) to assess the diversity of the pfhrp2 (and pfhrp3),
pldh and aldolase genes in P. falciparum and P. vivax isolates
from the various epidemiological strata for malaria in
Madagascar and (ii) to determine the potential effect of
this diversity on the performance of RDTs for malaria.
Methods
Study sites and parasite isolates
Two hundred sixty P. falciparum and one hundred twenty
seven Plasmodium vivax isolates from 16 sites throughout
Madagascar were collected in 2006 and analysed. These
samples included 160 P. falciparum and 55 P. vivax isolates
obtained from febrile inpatients at ten district hospitals
and identified by microscopy. A further 172 samples (100
P. falciparum and 72 P. vivax) were collected from febrile
outpatients attending six primary health centres. These
patients tested positive for malaria with RDTs based on
the detection of Plasmodium-specific lactate dehydroge-
nase (pLDH) (OptiMAL-IT™, DiaMed AG©, Cressier sur
Morat, Switzerland). The diagnosis was confirmed by
microscopy. These additional samples were not used for
assessment of the genetic diversity of Plasmodium lactate
dehydrogenase. All blood samples were stored dry spots
on filter paper. The geographic distribution of the samples
is shown in Figure 1.
DNA extraction
DNA was extracted from blood spots, using Instagene®
Matrix resin (BioRad©, Marnes la Coquette, France),
according to the manufacturer's instructions. The identifi-
cation of parasite species was confirmed by real-time PCR,
using species-specific primers, as previously described by
de Monbrison [14], and a protocol adapted for use with
the RotorGene® 3000 thermocycler (Corbett Life Science®,
Sydney, Australia).
Amplification by polymerase chain reaction
For P. falciparum, PCR amplification was carried out in a
final reaction volume of 55 μl containing DNA template,
primers (0.2 μM for each primer), dNTPs (Eurobio© 360
μM for each dNTP), 2.5 mM MgCl2 and 2.5 U FIREPol
(Solis Biodyne©). The primers were designed to amplify
exon 2 of the Pfhrp2 gene (PfHRP2-R and PfHRP2-F) and
the Pfhrp3 gene (HRP3-R1 and HRP3-F2), exon 2 of theMalaria Journal 2008, 7:219 http://www.malariajournal.com/content/7/1/219
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Pf-aldolase gene (Pf aldolase R1 and Pf aldolase F1) and
the Pf-lactate dehydrogenase gene (PfLDH-R1 and PfLDH-
F1). The primer sequences are shown in Table 1. PCR
amplification conditions were identical for all four genes:
denaturation at 94°C for 5 min, followed by 45 cycles of
94°C for 30 s, 57°C for 40 s and 72°C for 90 s, with a
final extension phase at 72°C for 10 minutes.
Plasmodium vivax DNA was amplified by nested PCR. The
outer PCR was carried out in a final volume of 20 μl con-
taining DNA template, 0.25 μM of each primer, 2.5 mM
MgCl2, 200 μM of each dNTP (Eurobio©) and 1 U of FIRE-
Pol (Solis Biodyne©). The inner PCR was performed in a
final reaction mixture of 55 μl containing PCR amplicons,
0.27 μM of each primer, 2.5 mM MgCl2, 360 μM of each
dNTP (Eurobio©) and 2.5 U of FIREPol (Solis Biodyne©).
The primer sequences used to amplify the P. vivax fructose
1,6-bisphosphate aldolase gene (outer primers, Pvald PF and
Pvald PR; inner primers, Pvald NF and Pvald NR) and P.
vivax L-lactate dehydrogenase gene (outer primers, Pvldh PF
and Pvldh PR; inner primers, Pvldh NF and Pvldh NR) are
shown in Table 1. After denaturation at 94°C for 4 min-
utes, the DNA was subjected to 40 cycles of 94°C for 20 s,
57°C for 20 s and 72°C for 80 s, with a final extension
phase at 72°C for 10 minutes, for the outer PCR. Similar
conditions were used for the inner PCR, but with different
Geographic distribution of the 387 samples (260 P. falciparum and 127 P. vivax) collected in 2006 at 16 sites throughout Mada- gascar Figure 1
Geographic distribution of the 387 samples (260 P. falciparum and 127 P. vivax) collected in 2006 at 16 sites 
throughout Madagascar.
 
Tsiroanomandidy (39 Pf, 52 Pv)
Tuléar (12 Pf)
Sambava (17 Pf) 
Manakara (2 Pf)
Mahajanga (21 Pf)
Antsiranana (13 Pf, 2 Pv) 
Sainte Marie (5 Pf)
Antsohihy (26 Pf)
Fianarantsoa (16 Pf, 1 Pv)
Mahitsy (9 Pf)
Ejeda (20 Pf, 11 Pv)
Miandrivazo (20 Pf, 31 Pv)
Ihosy (20 Pf, 1 Pv)
Maevatanana (20 Pf, 23 Pv)
Moramanga (20 Pf, 5 Pv)
Tropical stratum
Sub-desert Stratum
Highlands  stratum
Equatorial stratum
Farafangana (1 Pv)
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hybridization (58°C for 20 s) and elongation (72°C for
70 s) temperatures. Positive and negative controls were
included in all assays (from the Malaria Research Refer-
ence Reagent Resource Center, MR4/ATCC, Manassas, Vir-
ginia: HRP II, MRA-67; HRP III, MRA-68, genomic DNA
from P. falciparum 3D7, MRA-102G and genomic DNA
from P. vivax ONG, MRA-341G).
Direct sequencing of PCR products
PCR products were visualised by agarose gel electrophore-
sis and purified by filtration through polyacrylamide P-
100 Gel (Bio-Gel P-100, BioRad®, Marnes-la-Coquette,
France) in 96-well plates (Millipore®, St. Quentin en Yve-
lines, France). Sequencing reactions were performed with
BigDye Terminator chemistry (BigDye v 3.1 Terminator,
Applied BioSystem®, Courtaboeuf, France) and a Gene-
Amp-9700 sequencer (Applied BioSystem®, Courtaboeuf,
France). Sequencing was carried out with 10 μl of 0.3 mM
EDTA par well, using an ABI 3700 automatic DNA
sequencer (Applied BioSystems®, Courtaboeuf, France).
Data analysis
Electrophoregrams were visualised and analysed with
CEQTM 2000 Genetic Analysis System software (Beck-
man Coulter TM). Sequences of insufficient quality were
either resequenced or rejected. Amino-acid sequences of
the corresponding proteins were deduced from the nucle-
otide sequences obtained. Nucleotide and amino-acid
sequences were compared with the reference sequences in
Table 1, using Bio Edit Sequence Alignment Editor Soft-
ware [15]. For P. falciparum histidine-rich proteins 2 and
3, the amino-acid repeat was identified by numerical code
(1–18), as described by Baker et al [10].
Statistical analysis
Based on the results of the analysis, isolates from the var-
ious sites were grouped into three distinct geographical
regions: the North (Antsiranana, Sambava, Antosohihy,
Mahajanga, Maevatanana and Sainte Marie), the Centre
(Tsiroanomandidy, Miandrivazo, Mahitsy and Moram-
anga) and the South (Fianarantsoa, Manakara, Ihosy,
Toliara and Ejeda).
The predictive model developed by Baker et al. was used
to assess whether an isolate would be detected, if present
at a density of ≤ 250 parasites/μl, by a RDT detecting
PfHRP2 [10]. PfHRP2 sequences were classified into four
groups as a function of the number of type 2 × type 7
repeats: group A (very sensitive) if the PfHRP2 sequence
contained a more than 100 type 2 × type 7 repeats, group
B (sensitive) if the number of type 2 × type 7 repeats was
between 50 to 100, group C (non sensitive) if there were
< 43 repeats and "borderline" group if the number of
repeats was between 44 and 49.
Table 1: PCR primers, amplicon sizes and accession number of reference sequences used in the study.
PCR primers 
named
PCR primers sequence 5' to 3' Target gene Amplicons 
size (bp)
GenBank accession number of 
reference sequences
Nucleotide Protein
PfHRP2-R TTAATGGCGTAGGCAATGTG P. falciparum histidine-rich 
protein II gene, exon 2
905 M13986 AAA51639
PfHRP2-F TGTGTAGCAAAAATGCAAAAGG
HRP3-R1 TGGTGTAAGTGATGCGTAGT P. falciparum histidine-rich 
protein III gene
546 AF202093 AAF14632
HRP3-F2 AAATAAGAGATTATTACACGAAAG
Pf aldolase R1 TTTCCTTGCCATGTGTTCAA P. falciparum aldolase gene, 
exon 2
924 J03084 AAA29716
Pf aldolase F1 AGCAGATGTTGCCGAAGAAT
PfLDH-R1 TTTCAGCTATGGCTTCATCAAA P. falciparum lactate 
dehydrogenase gene
922 DQ825436 ABH03417
PfLDH-F1 GCACCAAAAGCAAAAATCGT
Pvald PF CCACTGGATCCGAATATAAA P. vivax fructose 1,6-
bisphosphate aldolase gene
1091 AF247063 AAK43741
Pvald PR CTTTTCGTAAAGGGATGCT
Pvald NF CCTCAAACTACCCGCAGAAG 994
Pvald NR GGAGTTCGCTTCTGCTCTCT
Pvldh PF GTAGAGGCAGGTGAACACTC P. vivax L-lactate 
dehydrogenase gene
1063 DQ060151 AAY59419
Pvldh PR TCCTTTTAGTCTCCGCAAC
Pvldh NF AACCCAAAATTGTGCTCGTC 900
Pvldh NR CGTCGAACTTGGTCTTCTCCMalaria Journal 2008, 7:219 http://www.malariajournal.com/content/7/1/219
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Differences in the presence/absence of amino-acids
repeats in isolates from different geographical areas were
assessed by carrying out χ2 tests, and differences in the
mean number of amino-acid repeats between the three
regions were assessed for each type of repeat, using the
Kruskall-Wallis test (H test). P values < 0.05 were inter-
preted as indicating statistically significant differences.
Results
Polymorphisms in PfHRP2
For the 260 samples collected, 229 PCR pfhrp2 fragments
were successfully amplified. These fragments ranged in
size from 435 to 927 bp, giving proteins of 145 to 309
amino acids. Thirteen of the 14 different amino-acid
repeats previously identified were detected [10]. Two hun-
dred twenty one unique PfHRP2 sequences were identi-
fied, 213 of which were found in only one isolate and
eight of which were found in two isolates. All PfHRP2
sequences had a similar structure: the type 1 repeat at the
start (100% of the sequences), the central motif with the
type 7, 8, 2, and 7 repeats combination (66.3% of the
sequences) and the type 12 repeat at the end (100% of the
sequences). Some repeats were observed in all PfHRP2
sequences (types 1, 2, 6, 7 and 12), whereas others were
not observed (repeat 9) or were found in only a few
sequences (repeat 8: 97.6%; repeat 3: 92.7%; repeat 10:
89.1%; repeat 5: 83.1%; repeat 4: 24.1%; repeat 13: 9.6%;
repeat 14: 8.4% and repeat 11: 0.4%). No differences in
the presence/absence of each repeat were found between
the three geographic regions (P > 0.05). Further details are
provided in Table 2.
Significant differences between the number of repeats as a
function of geographic region were seen for repeats 5 and
6: isolates from the South had significantly larger num-
bers of type 5 repeats than isolates from the North and
Centre and fewer type 6 repeats than isolates from the
North and Centre (Table 3).
Based on the model of Baker et al, the frequency of non
sensitive isolates (Group C, not detected for parasitaemia
≤ 250 parasites/μl) were predicted to be 9%. No signifi-
cant differences were found between the three regions in
the frequency of the four groups of Baker's model (P >
0.05) (Table 4).
Polymorphisms in the PfHRP3 gene
For PfHRP3, 238 PCR fragments were successfully ampli-
fied. They ranged in size from 405 to 720 bp and from the
corresponding protein sequences were 135 to 240 amino
acids long. Seven of the eight previously described amino-
acid repeats were identified [10]. One hundred five
unique PfHRP3 sequences were identified: 60 were
observed only once, 25 were observed twice, four
sequences were shared by three or seven isolates, three
sequences were found in four, five and twelve isolates and
one sequence was present in six, eight and eleven isolates.
All PfHRP3 sequences started with the type 1 repeat and
ended with a combination of the type 17 and type 4
repeats.
All repeats found in Madagascar were observed in all
PfHRP3 sequences (types 1, 4, 7, 15, 16, 17, 18). No dif-
ferences in the presence/absence of each repeat were
found between the three geographic regions (P > 0.05).
Further details are provided in table 2. No significant dif-
ference in the number of repeats was observed between
the different geographic regions (Table 3).
Polymorphisms in the aldolase gene
Comparisons of 240 P. falciparum aldolase gene
sequences obtained from 260 isolates collected through-
out Madagascar showed a high level of conservation. Only
four single nucleotide polymorphisms (SNP) were
observed in six isolates (Table 5). The two parasites with
the SNP at nucleotide 815 (amino-acid change at codon
104: H to R) originated from the North (Antsohihy and
Maevatanana), whereas the two parasites with the SNP at
nucleotide 1404 (amino-acid change at codon 300: H,
basic polar amino acid to Q, neutral polar amino acid)
originated from the North (Antsiranana) and South
(Ejeda). The other two SNPs found in one isolate origi-
nated from the South: Ihosy for the SNP at nucleotide
1314 (non synonymous change) and Ejeda for the SNP at
nucleotide 1417 (amino-acid change at codon 305: T,
neutral polar amino acid to A, neutral non-polar amino
acid).
For the 110 P. vivax aldolase gene sequences, only two
synonymous changes were observed. The SNP at nucle-
otide 510 were found in one isolate from the Centre
(Tsiroanomandidy) whereas the SNP at nucleotide 651
was observed in 43 isolates from the three regions (Table
5).
Polymorphisms in the pLDH gene
Two SNPs were observed among the 137 DNA sequences
obtained from the 160 P. falciparum isolates. The SNP at
nucleotide 73 (amino-acid change at codon 25: Q, neutral
polar amino acid to A, basic polar amino acid) was found
in one isolate from Tsiroanomandidy. In addition, 10 iso-
lates displayed a change of nucleotide at position 814
with respect to the reference sequence, resulting in an
amino acid change (D, acidic polar amino acid to N, neu-
tral polar amino-acid). These isolates came from the Cen-
tre (Mahitsy and Tsiroanomandidy) and the South
(Fianarantsoa and Tulear) (Table 5).
Greater diversity in the aldolase gene was observed for P.
vivax, with seven different nucleotide changes, includingMalaria Journal 2008, 7:219 http://www.malariajournal.com/content/7/1/219
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two non-synonymous amino-acid changes. Three synony-
mous amino-acid changes were frequent and found in all
three geographic regions (nucleotide changes at nucle-
otides 225, 627 and 687). The other four nucleotide
changes were rare. The change at nucleotide 405 was dis-
played by two isolates, one from Miandrivazo and one
from Maevatanana, and the change at nucleotide 168
(amino acid change from V to I, two neutral non polar
amino acids) was displayed by one isolate from Ejeda. The
other two changes were observed in two isolates from
Miandrivazo: at nucleotide 168 (amino-acid change from
D, acidic polar amino acid to N, neutral polar amino acid)
and at nucleotide 498 (Table 5).
Discussion
With the abandon of the inexpensive anti-malarial drug
treatments, such as chloroquine, and the use of ACT as a
first-line treatment, parasitological confirmation of sus-
pected cases of malaria has become essential. RDTs are
now indispensable tools in malaria management, particu-
larly in countries with endemic malaria in which health
structures are under-equipped. The WHO has issued some
recommendations, but the choice of RTD remains diffi-
cult for most users in endemic countries [16,17]. Indeed,
in addition to traditional considerations, such as the Plas-
modium species to be detected, the stability of storage and
use conditions, ease of use and cost, other technical
aspects must be taken into account. One of the most
important, but least studied of these factors is genetic var-
iability of the antigens detected by the antibody compo-
nent of the RTD. Indeed, very few data are currently
available, and the available data relate only to continental
level [10-13]. There is, therefore, clearly a need for more
data on pLDH and aldolase antigen variation and the geo-
graphic extent of HRP2 variation, especially at local level.
This study provides the first country-wide evaluation of
genetic polymorphism for the P. falciparum and P. vivax
antigens detected by RDTs for malaria, these two species
being the principal species of Plasmodium species found in
Madagascar [18-20].
Consistent with previous reports [10], the PfHRP2 antigen
(and the PfHRP3 antigen) was found to be highly diverse
in parasite isolates throughout Madagascar. However, No
significant differences, other than the number of repeats
for repeats 5 (AHHAHHASD) and 6 (AHHATD), were
found in the PfHRP2 and PfHRP3 sequences in the three
distinct geographic regions. The sequences obtained were
compared with others from around the world [10]. Mala-
gasy HRP2 sequences had certain characteristics in com-
mon with African isolates, particularly those from
Cameroon (presence of repeats 11, 13 and 14), and with
Asian/Pacific isolates, especially those from Thailand
(presence of repeats 13 and 14), the Philippines (presence
of repeat 11), Papua New Guinea (presence of repeat 14)
Table 2: Distribution of amino-acid repeats in PfHRP2 and PfHRP3 from parasites collected throughout Madagascar in 2006.
No. of amino acid 
repeats in PfHRP2 
and PfHRP3
Region and City
North Centre South Total
ATS SBV ATH MJG MAE STM TDD MIA MHT MOR FNR MNK IHO TLR EJE
1 AHHAHHVAD 1–5 1–5 1–6 1–5 1–5 2 1–5 1–4 1–3 1–4 2–4 3 1–4 1–4 1–4 1–6
1 AHHAHHVAD 1 1–2 1–3 1–3 1 1 1–3 1–3 1–2 1 1–2 1 1–4 1 1 1–4
2 AHHAHHAAD 8–16 11–13 10–14 4–15 8–14 14 10–14 11–13 11–12 10–13 8–15 12 8–14 7–14 7–15 4–16
3 AHHAHHAAY 0–2 1–2 1–2 0–2 0–2 0 1–2 1–2 1–2 1–2 1–2 0 1–2 1–3 0–3 0–3
4 AHH 0–1 0–1 0–1 0–3 0–2 0 0–1 0–1 0–1 0–1 0 1 0 0–1 0–1 0–3
4 A H H 1 1 1 – 2 1 11 1 1 1 1 1111 1 1 – 2
5 AHHAHHASD 0–1 1 0–3 0–1 0–1 1 0–2 0–2 1 0–1 0–3 0 0–2 1–2 0–2 0–3
6 AHHATD 3–5 3–5 2–5 2–7 2–6 2 2–8 2–6 3–5 3–8 1–3 3 1–3 2–4 2–5 1–8
7 AHHAAD 2–10 4–7 4–11 3–8 4–8 6 3–9 3–8 5–8 3–10 4–13 6 5–10 4–9 3–8 2–13
7 A H H A A D 111 1 1 1 1 11111 1 0 – 1 1 0 – 1
8 AHHAAY 1–2 1–2 1–2 1–2 1–2 1 0–2 0–2 1–2 0–2 0–2 3 0–2 1–2 1–2 0–2
9 A A Y 0 0 00 00 0 0 0 0 0000 00
10 AHHAAAHHA
TD
0–2 0–2 1–3 1–3 1–2 2 0–2 0–2 2–3 1–2 0–2 1 1–2 0–2 0–2 0–3
1 1 A H N 000 0 – 1 0 0 0 00000 0 0 0 0 – 1
12 AHHAAAHHE
AATH
1 1 11 11 1 1 1 1 1111 11
13 AHHASD 0–1 0–2 0–1 0 0–1 0 0–1 0–1 0 0–1 0 0 0–1 0 0–1 0–2
14 AHHAHHATD 0–2 0 0–1 0–1 0–1 0 0–1 0–1 0–1 0–1 0 0 0–1 0–1 0–1 0–2
1 5 A H H A A Y 1 1 11 11 10 – 1 1 1 1111 1 0 – 1
16 AAY 8–14 8–13 7–13 9–13 8–18 10–14 10–14 10–16 8–14 8–15 8–14 15 10–14 8–15 7–14 7–18
17 AHHAAAHHATD 1–8 5–9 5–8 4–7 5–8 4–8 5–7 3–7 5–10 0–7 4–10 6 4–8 4–6 3–8 0–10
18 AHN 1–3 1–4 1–3 1–4 1–3 2–3 1–3 1–3 2 0–3 2 2 1–2 1–3 2–3 0–4Malaria Journal 2008, 7:219 http://www.malariajournal.com/content/7/1/219
Page 7 of 9
(page number not for citation purposes)
and the Solomon Islands (presence of repeats 11 and 14),
probably reflecting the diversity of populations currently
living in Madagascar but originating from Africa, India,
Asia, the Middle East and Europe [21].
Finally, Baker's regression model showed that only 91%
of the P. falciparum parasites were likely to be detected by
RDTs based on HRP2 detection at parasite densities ≤ 250
parasites/μl. We found that the predicted prevalence of
parasites undetectable at densities ≤ 205 parasites/μl
("non-sensitive" parasites) was intermediate between that
in Asia-Pacific (mean of 23%, range from 17% in South-
East Asia to 33% in Papua New Guinea) and that in Africa
or South America (0%). We also found that the prevalence
of non-sensitive isolates in Madagascar was higher in the
South (14%) than in the North (6%), the Centre having
an intermediate prevalence (10%). However, this trend
was not statistically significant (P  < 0.17). One of the
major issues linked to the high prevalence of non-sensi-
tive strains in southern Madagascar – an epidemic-prone
area – is the high proportion of individuals with low lev-
els of immunity in this region and likely to present clinical
symptoms even with a parasitaemia below 250 parasites/
μl, a level not generally considered life-threatening. The
use of RTDs based on PfHRP2 detection would probably
give false negative results in 10% to 20% of cases, leaving
patients untreated and therefore at risk of developing
severe complications. Indeed, parasitaemia undetectable
with RDTs might well occur among the non-immune
tourists visiting Madagascar, who would then probably go
on to develop clinical symptoms on their return to
Europe.
Unlike PfHRP2 (and PfHRP3), the P. falciparum and P.
vivax aldolase and pLDH genes appear to be highly con-
served among the Malagasy isolates sequenced, confirm-
ing published data [12,13]. Indeed, for the aldolase gene,
none of the P. vivax samples displayed an amino-acid
change and only three previously undescribed amino-acid
changes were identified for P. falciparum samples (at
Table 3: Comparison of the mean number of each type of repeat in PfHRP2 and PfHRP3 from parasites from different geographic 
areas.
PfHRP2 sequences PfHRP3 sequences
Type of 
repeats
Total 
(n = 229)
North 
(n = 90)
Centre 
(n = 81)
South 
(n = 58)
P Total 
(n = 237)
North 
(n = 90)
Centre 
(n = 84)
South 
(n = 63)
P
mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
12 . 6 1 . 2 2.7 1.4 2.3 1.0 2.66 1.17 0.58 1.1 0.4 1.1 0.4 1.1 0.4 1.2 0.5 0.70
2 12.0 1.8 12.1 2.1 12.1 1.1 11.5 2.3 0.81
31 . 4 0 . 6 1.2 0.7 1.5 0.5 1.5 0.6 0.15
40 . 3 0 . 5 0.3 0.6 0.3 0.5 0.1 0.4 0.47 1.0 0.1 1.0 0.1 1.0 0 1.0 0 0.36
50 . 9 0 . 6 0.8 0.5 0.9 0.4 1.3 0.7 0.03
63 . 4 1 ; 2 3.5 1.1 3.8 1.4 2.7 0.8 0.01
76 . 0 2 . 0 6.0 1.9 6.1 1.7 6.2 2.3 0.73 1.0 0.1 1.0 0 1.0 0 0.98 0.14 0.31
81 . 1 0 . 5 1.3 0.4 1.1 0.4 1.3 0.6 0.23
10 1.5 0.8 1.6 0.7 1.6 0.8 1.4 0.8 0.71
13 0.3 0.9 0.2 0.4 0.04 0.2 0,0 0,0 0.08
14 0.1 0.3 0.1 0.4 0.1 0.3 0.1 0.3 0.8
15 1.0 0.1 1.0 0 1.0 0.1 1.0 0 0.43
16 11.4 1.8 11.2 1.5 11.5 1.9 11.4 1.8 0.73
17 5.8 1.3 5.7 1.3 5.7 1.3 6.0 1.3 0.68
18 2.1 0.5 2.1 0.6 2.1 0.5 2.0 0.4 0.61
Table 4: Prediction of RDT detection sensitivity based on the regression model of Baker et al (1).
Region of Madagascar No. of type 2 × type 7 repeats goup (%)
Group A Group B "Borderline" Group Group C Total
North 11 (12) 65 (72) 9 (10) 5 (6) 90
Centre 4 (5) 57 (70) 12 (15) 8 (10) 81
South 7 (12) 36 (62) 7 (12) 8 (14) 58
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codons 104, 300 and 305). Similarly, we observed only
four amino-acid changes in the pLDH gene, two in P. fal-
ciparum isolates (at codons 25 and 272) and two in P.
vivax samples (at codons 56 and 182). Most P. vivax iso-
lates displayed nucleotide differences with respect to the
sequence of the reference strain used: 39.1% of Malagasy
isolates displayed a change at nucleotide 651 with respect
to the Belem strain aldolase gene sequence (accession no.
DQ060151), and 75.7% displayed a change at nucleotide
225, 28.8% at nucleotide 627 and 20.7% at nucleotide
687, with respect to the WDK strain pLDH gene sequence
(accession no. AF247063). There are two possible expla-
nations for this difference: sequencing errors for the refer-
ence strains used in this study or a specific feature of the
Malagasy isolates, these SNPs having never been described
before.
Conclusion
The findings of the present study confirm previous data
concerning the greater polymorphism of PfHRP2 and
PfHRP3 antigens than of P. falciparum and P. vivax aldo-
lase and pLDH antigens. Based on analysis of the PfHRP2
sequences from Madagascar, we predict that 9% of the
Malagasy isolates would not be detected at densities ≤ 250
parasites/μl, despite the recommendation to use RDTs
based on PfHRP2 detection in the health facilities of the
111 sanitary districts. Thus, in countries using this type of
RDT for PfHRP2 sequence detection, efforts should be
made to determine more accurately the prevalence of
non-sensitive parasites. The results of this study suggest
that the National Malaria Control Programme in Mada-
gascar should train its healthcare staff and the end-users of
RDTs to provide information concerning the possibility of
false-negative results for patients with clinical symptoms
of malaria, particularly in South Madagascar. RDTs based
on pLDH detection may also be a useful alternative to
HRP2-based RDTS, despite their lower sensitivity [22] and
stability [23].
Nucleotide sequence accession numbers
The nucleotide sequences reported here have been depos-
ited in the GenBank database under accession numbers
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EU589943 to EU589946 for P. falciparum aldolase gene
sequences, EU589947 to EU589948 for P. falciparum
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